RCS - ValiRx PLC - ValiRx launches new interactive investor website

ValiRxAnnouncement

20/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241220:nRST8515Qa&default-theme=true

RNS Number : 8515Q  ValiRx PLC  20 December 2024

20 December 2024

VALIRX PLC

("ValiRx" or the "Company")

 

ValiRx launches new interactive investor website

providing shareholders with a more proactive way of communication and enquiry
support

 

ValiRx, a life science company focusing on early-stage cancer therapeutics and
women's health, is pleased to announce the launch of our interactive investor
website.

 

For both existing and prospective shareholders, the new investor hub brings
all ValiRx content into a single integrated platform to better inform and
engage with investors and stakeholders, including:

●     Regulatory announcements

●     Reports

●     Presentations

●     Educational material

●     Interviews

●     Corporate research

 

The investor hub also provides an interactive online experience allowing
ValiRx stakeholders to comment on and ask the ValiRx team questions via a
portal which will be monitored and responded to in a timely manner.

 

The Company's AIM Rule 26 website address and all information required by AIM
Rule 26 remains unchanged.

 

How to sign up for the ValiRx investor hub:

1.    Visit www.valirx.com

2.    Follow the prompts to sign up for an investor hub account

3.    Complete your account profile

 

Mark Eccleston, CEO, commented:

"As a life sciences company focused on advancing cutting-edge therapies, it is
essential that we keep our shareholders informed and engaged throughout our
journey. InvestorHub enables us to identify and understand our investor base
more clearly, allowing us to tailor communications that highlight key
milestones, clinical developments, and the value of our progress. This ensures
our shareholders remain aligned with our mission to deliver innovative
solutions in healthcare."

 

Ends

 

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3
(https://valirx.com/s/cc8ef3)

 

 

 

 

 

 

The Directors are responsible for the release of this announcement.

 

For further information, please contact:

 

 Investor questions on this announcement         https://valirx.com/link/vPn48e (https://valirx.com/link/vPn48e)

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                      Tel: +44 (0) 2476 796496

                                                 www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                          Mark.Eccleston@valirx.com

 Shard Capital Partners LLP (Sole Broker)        Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                  +44 (0) 115 787 0206

                                                 www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                             lucy@vformation.biz

                                                 sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPGPWPUPCPWB